Calcium channel blockers improve prognosis of patients with coronavirus disease 2019 and hypertension.

BACKGROUND: Hypertension is considered an important risk factor for the coronavirus disease 2019 (COVID-19). The commonly anti-hypertensive drugs are the renin-angiotensin-aldosterone system (RAAS) inhibitors, calcium channel blockers (CCBs), and beta-blockers. The association between commonly used anti-hypertensive medications and the clinical outcome of COVID-19 patients with hypertension has not been well studied. METHODS: We conducted a retrospective cohort study that included all patients admitted with COVID-19 to Huo Shen Shan Hospital and Guanggu District of the Maternal and Child Health Hospital of Hubei Province, Wuhan, China. Clinical and laboratory characteristics were extracted from electronic medical records. Hypertension and anti-hypertensive treatment were confirmed by medical history and clinical records. The primary clinical endpoint was all-cause mortality. Secondary endpoints included the rates of patients in common wards transferred to the intensive care unit and hospital stay duration. Logistic regression was used to explore the risk factors associated with mortality and prognosis. Propensity score matching was used to balance the confounders between different anti-hypertensive treatments. Kaplan-Meier curves were used to compare the cumulative recovery rate. Log-rank tests were performed to test for differences in Kaplan-Meier curves between different groups. RESULTS: Among 4569 hospitalized patients with COVID-19, 31.7% (1449/4569) had a history of hypertension. There were significant differences in mortality rates between hypertensive patients with CCBs (7/359) and those without (21/359) (1.95% vs. 5.85%, risk ratio [RR]: 0.32, 95% confidence interval [CI]: 0.13-0.76, χ2 = 7.61, P = 0.0058). After matching for confounders, the mortality rates were similar between the RAAS inhibitor (4/236) and non-RAAS inhibitor (9/236) cohorts (1.69% vs. 3.81%, RR: 0.43, 95% CI: 0.13-1.43, χ2 = 1.98, P = 0.1596). Hypertensive patients with beta-blockers (13/340) showed no statistical difference in mortality compared with those without (11/340) (3.82% vs. 3.24%, RR: 1.19, 95% CI: 0.53-2.69, χ2 = 0.17, P = 0.6777). CONCLUSIONS: In our study, we did not find any positive or negative effects of RAAS inhibitors or beta-blockers in COVID-19 patients with hypertension, while CCBs could improve prognosis.

AgBrO3/Few-Layer g-C3N4 Composites: A Visible-Light-Driven Photocatalyst for Tetracycline Degradation.

The AgBrO3/few-layer g-C3N4 composite photocatalyst has been developed via an in-situ synthetic method. The structure, morphology, light response range, separation and migration efficiency of the photogenerated electron-hole pairs and element valence state of the as-obtained samples have been characterized. The tetracycline was used to discuss the photocatalytic activities of the samples. The photocatalytic degradation mechanism of the as-obtained composites was also researched. The analysis results show that the photocatalytic degradation property of the asobtained composite photocatalyst appears to the tendency of first increasing and then decreasing with increasing the amount of AgBrO3 under visible light illumination. When the mass ratio of AgBrO3 to g-C3N4 is 4:3, in 60 min, the photocatalytic degradation efficiency of the as-obtained composites reaches the maximum of 79%. It is 37% and 45% higher than that of pure AgBrO3 and g-C3N4, respectively. Moreover, the separation and migration efficiency of the photogenerated electron-hole pairs of the as-prepared composites are also enhanced. In addition, superoxide radicals and holes are the dominant active species during the photocatalytic degradation process.

Preparation and Characterization of Nanosized Bi-Doped SnO2/Reduced Graphene Oxide 3D Hybrids for Visible-Light-Driven Photocatalysis.

The nanosized Bi-doped SnO2/reduced graphene oxide 3D hybrids have been synthesized via one-step hydrothermal method. The structures, morphologies, photocatalytic activities of the as-prepared samples were discussed, respectively. The formation mechanism of the as-prepared hybrids was also proposed. Experimental results indicated that the usage amount of Bi2Sn2O7 obviously affected the photocatalytic performance of the as-prepared products. When it was 450 mg, the as-prepared sample possessed the band gap energy of 1.9 eV and the photocatalytic efficiency of 90% in 210 min for degradation of rhodamine B solution. In addition, triethylene tetramine and the as-prepared carbon hydrogel could act as reductant to synergistically reduce Bi2Sn2O7 into Bi-doped SnO2 particles during the formation of the hybrids.

Zn2SnO4-Reduced Graphene Oxide Nanohybrids for Visible-Light-Driven Photocatalysis.

Zn2SnO4-reduced graphene oxide photocatalysts were synthesized by using SnCl4 5H2O, Zn(NO3)2 · 6H2O and graphene oxide via hydrothermal process. The structure, morphology, specific surface area and photo response of the as-prepared nanocomposites were characterized by X-ray diffraction, Transmission electron microscopy, UV-vis diffuse reflectance spectra, Brunauer-emmett-teller surface area measurement and Photoluminescence emission spectra. Experimental results showed that the Zn2SnO4 nanoparticles, with 20-30 nm a size range, were uniformly dispersed on the surfaces of reduced graphene oxide. Moreover, the as-prepared Zn2SnO4-reduced graphene oxide photocatalysts exhibited enhanced photocatalytic activities for degradation of Rhodamine B compared to those of pure Zn2SnO4. When the amount of reduced graphene oxide was 4 wt%, it showed the highest photocatalytic efficiency of 99.7% for 240 min, and the photocatalytic efficiency was still 98.5% after it was recycled 4 times. It also possessed the band gap of 2.48 eV and specific surface area of 58.1 m2 g-1.

[Diltiazem enhances food intake and gastrointestinal function in rats].

The present study was to investigate the effects of diltiazem, a ghrelin receptor agonist, on food intake and gastrointestinal functions in rats. Rats were intragastrically administered with diltiazem solution (daily 16 mg/kg, 30 mg/kg or 80 mg/kg, 30 d), and the rats with saline as control. To detect the effects of diltiazem on food intake and body weight, the average daily food intake and body weight were recorded, and the serum metabolic hormones of plasma growth hormone (GH) and neuropeptide Y (NPY) were tested by radioimmunoassay. By means of the spectrophotometer and the modified Mett's method, the effects of diltiazem on rat's gastrointestinal function and pepsin activity were tested, respectively. In addition, the gastric juice's acidity of rats was detected by titration and the secretion amount was calculated. The results showed that the food intake and body weight were maximally promoted by diltiazem at the dose of 30 mg/kg daily (30 d). The average daily food intake and body weight were significantly increased, and the serum concentrations of GH and NPY were also remarkably increased in diltiazem-treated groups compared with those in control group. The results also showed that the gastric emptying rate, gastric acid secretion and the activity of pepsin were significantly increased in diltiazem-treated group compared with those in control group. These results suggest that diltiazem induces enhancement of eating, in the same time, it can also stimulate the gastrointestinal function and regulate growth of rat.